Applied Genetic Technologies

Applied Genetics Technologies Corporation (AGTC) is developing therapies designed to transform the lives of patients with severe diseases, offering hope to patients with unmet medical needs. With a highly specialized team of physicians and researchers, They use cutting-edge techniques to develop treatments for patients that have diseases caused by broken genes. They use gene therapy, which replaces those broken genes with normal functional genes, allowing a patient’s own body to produce proteins to treat their illness. A single injection provides long-lasting treatment, leading to a better quality of life for patients worldwide.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

-AGTC patient advocacy executive director will address genetic testing and gene therapy for the treatment of rare retinal diseases-

AGTC to Participate in Envision Virtual Conference East 2021 Panel Discussion

GAINESVILLE, Fla., and CAMBRIDGE, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, today announced that management will be participating in the following virtual investor conferences:

AGTC to Participate at Upcoming Investor Conferences

Applied Genetic Technologies Corporation is a mid-clinical-stage biotechnology company developing genetic therapies for rare and debilitating diseases. AGTC's initial focus is on ophthalmology (study of medical conditions relating to the eye) where AGTC has active programs for X-linked retinitis pigmentosa, achromatopsia, and optogenetics.

Applied Genetic Technologies: Weak Early Clinical Ocular Results Highlight Increased Risk

- Activities to support the next stage of clinical development of ACHM B3 candidate are ongoing-

AGTC Reports 12-Month Data from its Ongoing Phase 1/2 Achromatopsia Clinical Trials Showing Biologic Activity in Patients with Mutations in the ACHM B3 Gene

GAINESVILLE, Fla. and CAMBRIDGE, Mass., June 23, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, today announced that it plans to release 12-month data for adult patients and low dose pediatric patients in its Phase 1/2 clinical Achromatopsia (ACHM) trials on Thursday, June 24, 2021. AGTC management will host a conference call and webcast with accompanying slides beginning at 8:00 AM Eastern Time on the same date to review the ACHM CNGB3 and CNGA3 data and provide an update on the trials.

AGTC to Host Conference Call on June 24 at 8:00 AM ET to Discuss Achromatopsia 12-Month Data in its Ongoing CNGB3 and CNGA3 Phase 1/2 Clinical Trials

-AGTC patient advocacy executive director will highlight the state of gene therapy  trial recruitment for IRDs-

AGTC to Present at American Optometric Association's Optometry's Meeting

Investors need to pay close attention to Applied Genetic Technologies (AGTC) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Applied Genetic Technologies (AGTC) Stock?

Genius Brands

Globalstar

Ideanomics Inc

Cenntro Electric Group

Nokia

Zomedica

Penny stocks are not usually on lists of must-buy stocks, but that does not mean these companies cannot explode in the coming weeks. The post 7 Penny Stocks To Watch Before They Pop Due to Reddit Users appeared first on InvestorPlace.

7 Penny Stocks To Watch Before They Pop Due to Reddit Users

Applied Genetic Technologies Corporation's (AGTC) CEO Sue Washer on Q3 2021 Results - Earnings Call Transcript

- Reported 50% response rate in visual sensitivity among patients in highest dose groups in ongoing Phase 1/2 clinical trial of its XLRP gene therapy candidate for patients who met inclusion criteria for Skyline and Vista trials -

AGTC Announces Financial Results and Business Update for the Quarter Ended March 31, 2021

GAINESVILLE, Fla., May 14, 2021 /PRNewswire/ -- Concept Companies, a Gainesville headquartered full-service real estate development and construction firm, has executed an agreement to commence development of a new laboratory facility for Applied Genetic Technologies Corporation (Nasdaq: AGTC).

Concept Companies Breaks Ground on Expansion for AGTC in Alachua's Foundation Park

Atossa Genetics

Clover Health Investments

Citius Pharmaceuticals

Senseonics Holdings

InvestorPlace is closing out a busy week of trading with a look at the Reddit penny stocks seeing the most chatter on Friday. The post 5 Reddit Penny Stocks Seeing the Most Chatter Friday appeared first on InvestorPlace.

5 Reddit Penny Stocks Seeing the Most Chatter Friday

- Company plans to lease 21,000 square foot build-to-suit cGMP manufacturing facility adjacent to its Florida facility -

AGTC Announces Expansion of Manufacturing and Analytics Capabilities to Advance Commercialization of Gene Therapy Product Candidates

AMC Entertainment

Precipio

Riot Blockchain

China Rapid Finance

It's time to take another look at penny stocks that are popular on Reddit as we dive into those getting the most attention on Thursday. The post 5 Reddit Penny Stocks Seeing the Most Chatter Thursday appeared first on InvestorPlace.

5 Reddit Penny Stocks Seeing the Most Chatter Thursday

Applied Genetic Technologies Corporation (NASDAQ: AGTC) has announced additional data from the ongoing X-linked retinitis pigmentosa (XLRP) gene therapy Phase 1/2 trial, including 12-month data from Groups 5 & 6 and 24-month data from two of three Group 4 patients. Groups 5 and 6 had a 50% response rate among patients who met the inclusion criteria for the Skyline and Vista trials.

Applied Genetic's XLRP Gene Therapy Shows Improved, Durable Response In Retinal Sensitivity

-Groups 5 and 6 had a 50% response rate among patients who met the inclusion criteria for the Skyline and Vista trials-

AGTC Reports Positive 12-Month Data from Highest Dose Groups in its Ongoing XLRP Phase 1/2 Clinical Trial

GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare retinal diseases, today announced that it plans to release 12-month data for Groups 5 and 6 evaluating durability of effect and continued safety at higher doses and 24-month data evaluating durability from a subset of Group 4 patients for its Phase 1/2 clinical trial in patients with X-linked Retinitis Pigmentosa (XLRP) on Thursday, May 6, 2021. AGTC management will host a conference call and webcast with accompanying slides to review the data and provide a general update on the XLRP trial beginning at 8:00 AM Eastern Time on the same date.

AGTC to Host Conference Call on May 6 at 8:00 AM ET to Discuss XLRP Full 12-Month Data from Highest Dose Groups and 24-Month Data from a Subset of Group 4 Patients of its Ongoing Phase 1/2 Clinical Trial

GAINESVILLE, Fla. and CAMBRIDGE, Mass., May 04, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced the presentation of two abstracts at the upcoming American Society of Gene & Cell Therapy (ASGCT) 24th Annual Meeting. The abstracts report new data from research-stage retinal studies of novel AAV vectors to support clinical phase product release for the X-linked retinitis pigmentosa (XLRP) clinical Phase 2/3 Vista study and manufacturing process improvements for future clinical trials. The ASGCT Annual Meeting is being held virtually May 11-14, 2021.

AGTC Advances in AAV Gene Therapy Manufacturing to be Presented at the American Society of Gene & Cell Therapy 24th Annual Meeting

-Company remains on track to present additional 12-month data from the XLRP and achromatopsia clinical trials in the second quarter of 2021-

AGTC Clinical Investigators Provide Encore Presentation of Data from the Company's Ongoing XLRP and Achromatopsia Phase 1/2 Trials

GAINESVILLE, Fla. and CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that data from the ongoing X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM) clinical trials will be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Virtual Annual Meeting. Paul Yang, MD, PhD, will present interim data from the XLRP Phase 1/2 trial and Mark Pennesi, MD, PhD, will present interim data from the ACHM Phase 1/2 clinical trials.

AGTC Announces Data to be Presented from the Ongoing XLRP and Achromatopsia Clinical Trials at the ARVO 2021 Virtual Annual Meeting

GAINESVILLE, Fla. and CAMBRIDGE, Mass., April 26, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that Mark Shearman, Ph.D., Chief Scientific Officer, has resigned from the company to pursue another opportunity but will remain to facilitate a smooth transition through June 4, 2021.

AGTC Announces Departure of Chief Scientific Officer

- AGTC Transfers Clinical Trial Materials and Phase 1/2 Data To TeamedON -

TeamedOn and AGTC Announce a Licensing Agreement Advancing X-Linked Retinoschisis Gene Therapy Program

GAINESVILLE, Fla. and CAMBRIDGE, Mass., March 31, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that Company management will participate in the following virtual conferences:

AGTC to Participate in Upcoming Virtual Biotech Corporate Access Day and Cell and Gene Conference

-AGTC's deep commitment to the patient voice drives solutions to support patient access to information and to improve the experience of patients participating in clinical trials-

AGTC Announces New Initiatives To Enhance The Patient Journey In Its XLRP Trials

-AGTC will highlight the value of the patient voice in gene therapy development-

News for Applied Genetic Technologies Stock (AGTC)